Sec Form 4 Filing - Funtleyder Leslie D. @ Applied Therapeutics, Inc. - 2024-12-19

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Funtleyder Leslie D. 2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics, Inc. [ APLT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400 3. Date of Earliest Transaction (MM/DD/YY) 12/19/2024 (Street) NEW YORK, NY10017 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/19/2024 A 150,000 ( 1 ) A $ 0 427,911 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.02 12/19/2024 A 150,000 ( 2 ) ( 2 ) 12/19/2034 Common Stock 150,000 $ 0 150,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Funtleyder Leslie D. C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK, NY10017 X See Remarks Signatures /s/ Leslie D. Funtleyder 12/20/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of compensatory Restricted Stock Units ("RSUs") granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan") in connection with the Reporting Person's service as interim Chief Executive Officer. Each compensatory RSU represents a contingent right to receive one share of the issuer's common stock. The compensatory RSUs will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested RSUs will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan). ( 2 )Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

Remarks: Interim Chief Executive Officer and Chief Financial Officer

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.